A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma

Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136

Dvorak, 2002, Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy, J Clin Oncol, 20, 4368, 10.1200/JCO.2002.10.088

Kumar-Singh, 1997, Evaluation of tumor angiogenesis as a prognostic marker in malignant mesothelioma, J Pathol, 182, 211, 10.1002/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D

Edwards, 2001, Angiogenesis is an independent prognostic factor in malignant mesothelioma, Br J Cancer, 85, 863, 10.1054/bjoc.2001.1997

Kumar-Singh, 1999, Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression, J Pathol, 189, 72, 10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0

Strizzi, 2001, Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma, J Pathol, 193, 468, 10.1002/path.824

Masood, 2003, Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops, Int J Cancer, 104, 603, 10.1002/ijc.10996

Konig, 1999, Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma, Virchows Arch, 435, 8, 10.1007/s004280050388

Soini, 2001, Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1, or FLT1, Histopathology, 39, 179, 10.1046/j.1365-2559.2001.01211.x

Karrison, 2007, Final analysis of a multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM), J Clin Oncol, 18s

Curran, 1998, Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer Experience, J Clin Oncol, 16, 145, 10.1200/JCO.1998.16.1.145

Byrne, 2004, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma, Ann Oncol, 15, 257, 10.1093/annonc/mdh059

Ranpura, 2011, Treatment-related mortality with bevacizumab in cancer patients, JAMA, 305, 487, 10.1001/jama.2011.51

Scappaticci, 2007, Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab, J Natl Cancer Inst, 99, 1232, 10.1093/jnci/djm086

Ranpura, 2010, Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials, Acta Oncol, 49, 287, 10.3109/02841860903524396

Azzi, 2010, Bevacizumab (Bev) and the risk of arterial thromboembolic events (ATE) in patients with renal cell carcinoma and other cancers: a large comprehensive meta-analysis of more than 13,000 patients, J Clin Oncol, 28, 10.1200/jco.2010.28.15_suppl.4609

Nalluri, 2008, Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis, JAMA, 300, 2277, 10.1001/jama.2008.656

Hurwitz, 2011, Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies, J Clin Oncol, 29, 1757, 10.1200/JCO.2010.32.3220

Jahan, 2012, Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107), Lung Cancer, 76, 393, 10.1016/j.lungcan.2011.11.014

Kindler, 2001, SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study, Proc Am Soc Clin Oncol, 20

Laurie, 2011, Brief report: a phase II study of sunitinib in malignant mesothelioma. The NCIC clinical trials group, J Thorac Oncol, 6, 1950, 10.1097/JTO.0b013e3182333df5

Garland, 2011, Phase II study of cediranib in patients with malignant pleural mesothelioma SWOG S0509, J Thorac Oncol, 6, 1938, 10.1097/JTO.0b013e318229586e

Dubey, 2010, A phase II study of sorafenib in malignant mesothelioma results of Cancer and Leukemia Group B 30307, J Thorac Oncol, 5, 1655, 10.1097/JTO.0b013e3181ec18db

Baas, 2005, Thalidomide in patients with malignant pleural mesothelioma, Lung Cancer, 48, 291, 10.1016/j.lungcan.2004.10.005

Pavlakis, 2003, Thalidomide alone or in combination with cisplatin/gemcitabine in malignant pleural mesothelioma: interim results from two parallel non randomized phase II studies, Lung Cancer, 41, S11, 10.1016/S0169-5002(03)91684-9

Buikhuisen, 2011, A multicenter, randomized phase III maintenance study of thalidomide (Arm A) versus observation (Arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy, J Thorac Oncol, 6

Ceresoli, 2011, Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma (MPM), J Thorac Oncol, 6